{
    "clinical_study": {
        "@rank": "114535", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Study further the safety and efficacy of the alpha-receptor agonist\n      midodrine in patients with neurogenic orthostatic hypotension.\n\n      II.  Assess the quality of life in these patients with this treatment regimen."
        }, 
        "brief_title": "Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension", 
        "condition": "Orthostatic Hypotension", 
        "condition_browse": {
            "mesh_term": [
                "Hypotension", 
                "Hypotension, Orthostatic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a partially randomized, multicenter study. Patients receive oral\n      midodrine three times a day during weeks 1 and 3-5, then either oral midodrine or placebo\n      for weeks 6-8.\n\n      Quality of life is assessed at weeks 3, 6, and 8."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Orthostatic hypotension due to autonomic nervous system\n        failure, i.e.: Fall in systolic blood pressure (supine to standing) of at least 15 mm Hg\n        AND Symptoms of dizziness, lightheadedness, unsteadiness with a severity of 4.5 or less on\n        a 10 point scale in 2 of 3 evaluations over a 3 day period --Prior/Concurrent Therapy-- No\n        concurrent sympathomimetics or alpha-receptor agonists or antagonists No concurrent drug\n        with significant smooth muscle relaxant or constrictive properties e.g., calcium channel\n        blockers At least 30 days since other prior investigational agents --Patient\n        Characteristics-- Hepatic: No coagulopathy Renal: No acute nephritis or chronic renal\n        failure Cardiovascular: No sustained supine hypertension greater than 180/110 mm Hg No\n        congestive heart failure No myocardial infarction within the last 6 months No uncontrolled\n        arrhythmia (ventricular tachycardia or second or third degree heart block not treated with\n        pacemaker) No unstable angina pectoris No history of cerebral vascular accident Other: No\n        pheochromocytoma No thyrotoxicosis No seizure disorder Not pregnant or nursing Negative\n        pregnancy test Fertile patients must use effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "300", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004268", 
            "org_study_id": "199/11645", 
            "secondary_id": "RLI-5894009"
        }, 
        "intervention": {
            "intervention_name": "midodrine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Midodrine"
        }, 
        "keyword": [
            "cardiovascular and respiratory diseases", 
            "disease-related problem/condition", 
            "orthostatic hypotension", 
            "quality of life", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "Mount Sinai School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Roberts Pharmaceutical", 
            "last_name": "Horacio Kaufmann", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004268"
        }, 
        "source": "National Center for Research Resources (NCRR)", 
        "sponsors": {
            "collaborator": {
                "agency": "Roberts Pharmaceutical", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2002"
    }, 
    "geocoordinates": {
        "Mount Sinai School of Medicine": "40.714 -74.006"
    }
}